Alpine Woods Capital Investors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Alpine Woods Capital Investors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-13,000	Closed	-$500K	–	449
2016 Q2	$500K	Hold	13,000	–	–	0.03%	300
2016 Q1	$495K	Hold	13,000	–	–	0.03%	301
2015 Q4	$572K	Hold	13,000	–	–	0.03%	314
2015 Q3	$529K	Buy	13,000 +3,000	+30%	+$132K	0.03%	323
2015 Q2	$533K	Buy	+10,000	New	+$531K	0.03%	312

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Alpine Woods Capital Investors's JUNO Position: Q3 2016 in Review

Alpine Woods Capital Investors sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 13,000 shares — an estimated $500K sold.

Alpine Woods Capital Investors first reported a position in JUNO in Q2 2015 and held it in 5 quarters. The position peaked at $572K in Q4 2015. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

Alpine Woods Capital Investors reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Alpine Woods Capital Investors sold 13,000 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $500K.
Alpine Woods Capital Investors first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 5 quarters.
Alpine Woods Capital Investors's Juno Therapeutics, Inc. position peaked at $572K in Q4 2015.
169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on Alpine Woods Capital Investors's 13F filing for Q3 2016, filed 9 Nov 2016.